Eligard
Photos »
/ 
Related News »
Last year`s reporting period included a non-recurring item, specifically EUR 20 million received for the sale of the Eligard ® rights to Medigene`s marketing partner Astellas, which was recorded as "discontinued operations" according to IFRS.
May 11, 2012 at 05:29 | Source: Yahoo Finance
the risk that sales of Visudyne ® or Eligard ® may be less than expected (including due to competitive products and pricing); and general economic conditions and other factors described in detail in QLT's Annual Report on Form 10-K, Quarterly Reports on ...
May 24, 2012 at 20:44 | Source: Stockhouse
or Eligard (R) may be less than expected (including due to competitive products and pricing); and general economic conditions and other factors described in detail in QLT's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other ...
May 24, 2012 at 06:25 | Source: Yahoo Finance
The company is back in growth mode, collecting royalties on drugs it developed – Visudyne (used to treat macular degeneration) and Eligard (a prostate cancer drug) – and has been in hiring mode. QLT's board warns shareholders that a change ...
May 24, 2012 at 17:59 | Source: Business in Vancouver
Last year's reporting period included a non-recurring item, specifically EUR 20 million received for the sale of the Eligard(®) rights to Medigene's marketing partner Astellas, which was recorded as "discontinued operations" according to IFRS. Combining ...
May 11, 2012 at 05:57 | Source: finanzen.net